JP2025513454A5 - - Google Patents

Info

Publication number
JP2025513454A5
JP2025513454A5 JP2024562078A JP2024562078A JP2025513454A5 JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5 JP 2024562078 A JP2024562078 A JP 2024562078A JP 2024562078 A JP2024562078 A JP 2024562078A JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5
Authority
JP
Japan
Prior art keywords
pain
compound
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019478 external-priority patent/WO2023205468A1/en
Publication of JP2025513454A publication Critical patent/JP2025513454A/ja
Publication of JP2025513454A5 publication Critical patent/JP2025513454A5/ja
Pending legal-status Critical Current

Links

JP2024562078A 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物 Pending JP2025513454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333881P 2022-04-22 2022-04-22
US63/333,881 2022-04-22
PCT/US2023/019478 WO2023205468A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2025513454A JP2025513454A (ja) 2025-04-24
JP2025513454A5 true JP2025513454A5 (cg-RX-API-DMAC7.html) 2026-04-28

Family

ID=86382967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562078A Pending JP2025513454A (ja) 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物

Country Status (7)

Country Link
US (1) US20250388543A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511115A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513454A (cg-RX-API-DMAC7.html)
CN (1) CN119546580A (cg-RX-API-DMAC7.html)
AU (1) AU2023257313A1 (cg-RX-API-DMAC7.html)
CA (1) CA3256248A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023205468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025256572A1 (zh) * 2024-06-13 2025-12-18 海思科医药集团股份有限公司 一种Nav1.8抑制剂及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7493493B2 (en) 2003-12-12 2009-02-17 International Business Machines Corporation Method and apparatus for password generation
WO2006011050A2 (en) 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
MX2011006904A (es) 2008-12-26 2011-07-20 Dainippon Sumitomo Pharma Co Compuesto heterociclico biciclico novedoso.
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
BR112014009102A2 (pt) 2011-10-26 2017-04-18 Pfizer Ltd compostos químicos
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013109521A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
CN105026373B (zh) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
BR112015018284B1 (pt) 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ナトリウムチャネルの調節剤としてのスルホンアミド
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
AU2016226340B2 (en) 2015-03-02 2019-11-07 Amgen Inc. Bicyclic ketone sulfonamide compounds
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス, インコーポレイテッド 疼痛の処置のための11,13−修飾サキシトキシン
CA3058214A1 (en) 2017-03-29 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University 11,13-modified saxitoxins for the treatment of pain
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
SG11202100130QA (en) 2018-07-09 2021-02-25 Lieber Institute Inc Pyridine carboxamide compounds for inhibiting nav1.8
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
GEAP202315648A (en) 2018-11-02 2023-07-25 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
WO2020140959A1 (zh) 2019-01-04 2020-07-09 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
WO2020151728A1 (zh) 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
MA56398A (fr) 2019-06-27 2022-05-04 Glaxosmithkline Ip Dev Ltd Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
TW202115038A (zh) 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
KR20220101606A (ko) 2019-09-12 2022-07-19 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 피리딘 산질화물 및 이의 제조 방법과 용도
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP7879815B2 (ja) 2020-06-10 2026-06-24 アムジエン・インコーポレーテツド ヘテロアルキルジヒドロキノリンスルホンアミド化合物
JP7880201B2 (ja) 2020-06-10 2026-06-25 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
CN115697327A (zh) 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
KR20230026404A (ko) 2020-06-17 2023-02-24 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
EP4196482B1 (en) 2020-08-14 2025-10-01 SiteOne Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114591293B (zh) 2020-12-07 2026-06-02 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
EP4334293A1 (en) 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
MX2023013147A (es) 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
US11999699B2 (en) 2021-06-15 2024-06-04 Grünenthal GmbH Substituted pyrazole amides

Similar Documents

Publication Publication Date Title
JP7770691B2 (ja) 抗ウイルス活性等の生理活性を有する化合物
JP2022169800A (ja) 細菌の排出ポンプ阻害剤
KR102585108B1 (ko) 세균 감염의 치료를 위한 항미생물성 폴리믹신
JP2017518959A5 (cg-RX-API-DMAC7.html)
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
JP2022524974A5 (cg-RX-API-DMAC7.html)
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
RU2010126056A (ru) Органические соединения
JP2022522694A5 (cg-RX-API-DMAC7.html)
RU2639153C2 (ru) Трициклическое бензоксабороловое соединение, способ его получения и его применение
JP2023531709A5 (cg-RX-API-DMAC7.html)
JP2022537140A5 (cg-RX-API-DMAC7.html)
EP2139889B1 (en) Amino-naphthyridine derivatives
EP4457214A2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
JP2010505865A5 (cg-RX-API-DMAC7.html)
JP2013528659A5 (cg-RX-API-DMAC7.html)
RU2003134629A (ru) Соединения цефема
EP1972338A1 (en) Anti-infective agents
JP2022509763A5 (cg-RX-API-DMAC7.html)
JP2008531701A5 (cg-RX-API-DMAC7.html)
JP7834842B2 (ja) 非対称gpr84拮抗剤およびその使用
JP2021530465A5 (cg-RX-API-DMAC7.html)
CN1436173A (zh) 羟基甲脒衍生物及含有该衍生物的药物
WO2023224128A1 (ja) 線維症の治療又は予防のための医薬組成物
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도